OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
COVID-19-associated thrombotic microangiopathy has emerged as a severe complication that exacerbates morbidity and mortality in critical cases. Thrombotic microangiopathy, characterized by ...
MCLEAN, Va.—The Monitoring Association (TMA) is entering a new chapter with the appointment of Whitney A. Doll as CEO and Alan Gillmore as president - two leaders with visions that promise to shape ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology,detailing survival outcomes in adult ...
MCLEAN, Va.—The Board of Directors of The Monitoring Association (TMA) has announced the appointment of Whitney A. Doll as the organization’s new CEO. A dynamic association executive with over 18 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback